Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission.

Trial Profile

Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Pidilizumab (Primary) ; Dendritic cell vaccines
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2019.
    • 09 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
    • 09 Dec 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top